Quantifying Longitudinal Cognitive Resilience to Alzheimer's Disease and Other Neuropathologies

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2022 Feb 1

PMID 35102704

Authors

Maude Wagner

Robert S Wilson

Sue E Leurgans

Patricia A Boyle

David A Bennett

Francine Grodstein

Ana W Capuano

Affiliations

Soon will be listed here.

Abstract

Introduction: Cognitive resilience (CR) has been defined as the continuum of better (or worse) than expected cognition, given the degree of neuropathology. To quantify this concept, existing approaches focus on either cognitive level at a single time point or slopes of cognitive decline.

Methods: In a prospective study of 1215 participants, we created a continuous measure of CR defined as the mean of differences between estimated person-specific and marginal cognitive levels over time, after accounting for neuropathologies.

Results: Neuroticism and depressive symptoms were associated with all CR measures (P-values < .012); as expected, cognitive activity and education were only associated with the cognitive-level approaches (P-values < .0002). However, compared with the existing CR measures focusing on a single measure or slopes of cognition, our new measure yielded stronger relations with risk factors.

Discussion: Defining CR based on the longitudinal differences between person-specific and marginal cognitive levels is a novel and complementary way to quantify CR.

Citing Articles

Single-cell multiregion dissection of Alzheimer's disease.

Mathys H, Boix C, Akay L, Xia Z, Davila-Velderrain J, Ng A Nature. 2024; 632(8026):858-868.

PMID: 39048816 PMC: 11338834. DOI: 10.1038/s41586-024-07606-7.

Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration.

Boyle R, Townsend D, Klinger H, Scanlon C, Yuan Z, Coughlan G Alzheimers Res Ther. 2024; 16(1):148.

PMID: 38961512 PMC: 11220971. DOI: 10.1186/s13195-024-01510-y.

Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration.

Sun M, Alkon D Trends Pharmacol Sci. 2024; 45(3):197-209.

PMID: 38360510 PMC: 10939773. DOI: 10.1016/j.tips.2024.01.012.

Estimating dementia risk in an African American population using the DCTclock.

Ciesla M, Pobst J, Gomes-Osman J, Lamar M, Barnes L, Banks R Front Aging Neurosci. 2024; 15:1328333.

PMID: 38274984 PMC: 10810014. DOI: 10.3389/fnagi.2023.1328333.

Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer's disease pathology.

Mathys H, Peng Z, Boix C, Victor M, Leary N, Babu S Cell. 2023; 186(20):4365-4385.e27.

PMID: 37774677 PMC: 10601493. DOI: 10.1016/j.cell.2023.08.039.

References

Corrada M, Berlau D, Kawas C . A population-based clinicopathological study in the oldest-old: the 90+ study. Curr Alzheimer Res. 2012; 9(6):709-17. PMC: 3409303. DOI: 10.2174/156720512801322537. View

Arvanitakis Z, Capuano A, Leurgans S, Bennett D, Schneider J . Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 2016; 15(9):934-943. PMC: 4969105. DOI: 10.1016/S1474-4422(16)30029-1. View

Wilson R, Yu L, Trojanowski J, Chen E, Boyle P, Bennett D . TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013; 70(11):1418-24. PMC: 3830649. DOI: 10.1001/jamaneurol.2013.3961. View

Han S, Nguyen C, Stricker N, Nation D . Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. Neuropsychol Rev. 2017; 27(4):305-325. PMC: 5681895. DOI: 10.1007/s11065-017-9345-5. View

Negash S, Wilson R, Leurgans S, Wolk D, Schneider J, Buchman A . Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition. Curr Alzheimer Res. 2013; 10(8):844-51. PMC: 4060425. DOI: 10.2174/15672050113109990157. View

Schneider J, Arvanitakis Z, Bang W, Bennett D . Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69(24):2197-204. DOI: 10.1212/01.wnl.0000271090.28148.24. View

Proust-Lima C, Amieva H, Jacqmin-Gadda H . Analysis of multivariate mixed longitudinal data: a flexible latent process approach. Br J Math Stat Psychol. 2012; 66(3):470-87. DOI: 10.1111/bmsp.12000. View

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413-446. PMC: 7392084. DOI: 10.1016/S0140-6736(20)30367-6. View

Bennett D, Buchman A, Boyle P, Barnes L, Wilson R, Schneider J . Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018; 64(s1):S161-S189. PMC: 6380522. DOI: 10.3233/JAD-179939. View

10.

Kapasi A, DeCarli C, Schneider J . Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017; 134(2):171-186. PMC: 5663642. DOI: 10.1007/s00401-017-1717-7. View

11.

Wilson R, Yu L, Lamar M, Schneider J, Boyle P, Bennett D . Education and cognitive reserve in old age. Neurology. 2019; 92(10):e1041-e1050. PMC: 6442015. DOI: 10.1212/WNL.0000000000007036. View

12.

Yu L, Tasaki S, Schneider J, Arfanakis K, Duong D, Wingo A . Cortical Proteins Associated With Cognitive Resilience in Community-Dwelling Older Persons. JAMA Psychiatry. 2020; 77(11):1172-1180. PMC: 7330835. DOI: 10.1001/jamapsychiatry.2020.1807. View

13.

Buchman A, Boyle P, Wilson R, Beck T, Kelly J, Bennett D . Apolipoprotein E e4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord. 2009; 23(1):63-9. PMC: 2662708. DOI: 10.1097/wad.0b013e31818877b5. View

14.

Neumann M, Kwong L, Lee E, Kremmer E, Flatley A, Xu Y . Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009; 117(2):137-49. PMC: 2693625. DOI: 10.1007/s00401-008-0477-9. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Wilson R, Barnes L, Krueger K, Hoganson G, Bienias J, Bennett D . Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc. 2005; 11(4):400-7. View

17.

Capuano A, Wilson R, Leurgans S, Sampaio C, Barnes L, Farfel J . Neuroticism, negative life events, and dementia in older White and Black Brazilians. Int J Geriatr Psychiatry. 2020; 36(6):901-908. PMC: 8384138. DOI: 10.1002/gps.5491. View

18.

Price J, McKeel Jr D, Buckles V, Roe C, Xiong C, Grundman M . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009; 30(7):1026-36. PMC: 2737680. DOI: 10.1016/j.neurobiolaging.2009.04.002. View

19.

Wilson R, Yu L, Leurgans S, Bennett D, Boyle P . Proportion of cognitive loss attributable to terminal decline. Neurology. 2019; 94(1):e42-e50. PMC: 7011688. DOI: 10.1212/WNL.0000000000008671. View

20.

Arenaza-Urquijo E, Vemuri P . Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. Neurology. 2018; 90(15):695-703. PMC: 5894932. DOI: 10.1212/WNL.0000000000005303. View